Display options
Cite
Lin LH, Xu YW, Huang LS, et al. Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma. Clin Proteomics. 2017;14:6doi: 10.1186/s12014-017-9141-5.
Lin, L. H., Xu, Y. W., Huang, L. S., Hong, C. Q., Zhai, T. T., Liao, L. D., Lin, W. J., Xu, L. Y., Zhang, K., Li, E. M., & Peng, Y. H. (2017). Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma. Clinical proteomics, 146. https://doi.org/10.1186/s12014-017-9141-5
Lin, Lie-Hao, et al. "Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma." Clinical proteomics vol. 14 (2017): 6. doi: https://doi.org/10.1186/s12014-017-9141-5
Lin LH, Xu YW, Huang LS, Hong CQ, Zhai TT, Liao LD, Lin WJ, Xu LY, Zhang K, Li EM, Peng YH. Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma. Clin Proteomics. 2017 Feb 01;14:6. doi: 10.1186/s12014-017-9141-5. eCollection 2017. PMID: 28184180; PMCID: PMC5289059.
Copy Download .nbib Format: NLM
Share it on

Clin Proteomics. 2017 Feb 01;14:6. doi: 10.1186/s12014-017-9141-5. eCollection 2017.

Serum proteomic-based analysis identifying autoantibodies against PRDX2 and PRDX3 as potential diagnostic biomarkers in nasopharyngeal carcinoma.

Clinical proteomics

Lie-Hao Lin, Yi-Wei Xu, Li-Sheng Huang, Chao-Qun Hong, Tian-Tian Zhai, Lian-Di Liao, Wen-Jie Lin, Li-Yan Xu, Kai Zhang, En-Min Li, Yu-Hui Peng

Affiliations

  1. Department of Clinical Laboratory Medicine, The Cancer Hospital of Shantou University Medical College, No. 7, Raoping Road, Shantou, 515041 Guangdong China.
  2. Department of Orthopaedics, The Nanao People's Hospital, Shantou, 515999 China.
  3. The Key Laboratory of Molecular Biology for High Cancer Incidence Coastal Chaoshan Area, Shantou University Medical College, Shantou, 515041 China.
  4. Department of Radiation Oncology, The Cancer Hospital of Shantou University Medical College, Shantou, 515041 China.
  5. Department of Oncological Laboratory Research, The Cancer Hospital of Shantou University Medical College, Shantou, 515041 China.
  6. Institute of Oncological Pathology, Shantou University Medical College, Shantou, 515041 China.
  7. Tianjin Key Laboratory of Medical Epigenetics, Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Tianjin Medical University, Tianjin, 300070 China.
  8. Department of Biochemistry and Molecular Biology, Shantou University Medical College, Shantou, 515041 China.

PMID: 28184180 PMCID: PMC5289059 DOI: 10.1186/s12014-017-9141-5

Abstract

BACKGROUND: Nasopharyngeal carcinoma (NPC) is a major head and neck cancer with high occurrence in Southeast Asia and southern China. We aimed to identify autoantibodies that may contribute to early detection of NPC.

METHODS: We used serological proteome analysis to identify candidate autoantibodies against tumor-associated antigens. Levels of autoantibodies and Epstein-Barr virus capsid antigen-IgA (VCA-IgA) were measured by ELISA in 129 patients with NPC and 100 normal controls. We employed receiver operating characteristics to calculate diagnostic accuracy.

RESULTS: Sera from patients with NPC yielded multiple spots, two of which were identified as PRDX2 and PRDX3. Levels of serum autoantibodies against PRDX2 and PRDX3 were significantly higher for patients with NPC than for normal controls (

CONCLUSIONS: This study reports autoantibodies against PRDX2 and PRDX3 identified by a proteomic approach in sera from NPC patients. Our findings suggest that autoantibodies against PRDX2 and PRDX3 may serve as supplementary biomarkers to VCA-IgA for the screening and diagnosis of NPC.

Keywords: Autoantibody; Early diagnosis; Nasopharyngeal carcinoma; Peroxiredoxin; Serological proteome analysis

References

  1. Cancer Med. 2016 Jul;5(7):1388-96 - PubMed
  2. Recent Results Cancer Res. 2007;174:179-87 - PubMed
  3. Chin J Cancer. 2010 May;29(5):517-26 - PubMed
  4. J Proteome Res. 2012 Apr 6;11(4):2452-66 - PubMed
  5. Trends Biochem Sci. 2003 Jan;28(1):32-40 - PubMed
  6. Am J Gastroenterol. 2014 Jan;109(1):36-45 - PubMed
  7. Annu Rev Pathol. 2006;1:375-404 - PubMed
  8. Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):1107-16 - PubMed
  9. Am J Pathol. 1995 Jun;146(6):1355-67 - PubMed
  10. Lung Cancer. 2014 Jan;83(1):51-5 - PubMed
  11. Nat Rev Cancer. 2003 Apr;3(4):243-52 - PubMed
  12. Antioxid Redox Signal. 1999 Winter;1(4):385-402 - PubMed
  13. Int J Cancer. 2014 May 1;134(9):2180-88 - PubMed
  14. Clin Cancer Res. 2006 Nov 1;12(21):6415-20 - PubMed
  15. Radiother Oncol. 2012 Sep;104(3):331-7 - PubMed
  16. J Proteome Res. 2005 Jul-Aug;4(4):1123-33 - PubMed
  17. Cancer Prev Res (Phila). 2015 Aug;8(8):729-36 - PubMed
  18. Cancer Epidemiol Biomarkers Prev. 2014 Sep;23 (9):1834-42 - PubMed
  19. Oncol Lett. 2014 Sep;8(3):1096-1102 - PubMed
  20. Chin J Cancer. 2012 Apr;31(4):185-96 - PubMed
  21. Cancer Lett. 2014 Feb 28;343(2):190-9 - PubMed
  22. Cancer Res. 2016 Sep 15;76(18):5467-78 - PubMed
  23. Oral Oncol. 2014 Jun;50(6):527-38 - PubMed
  24. Tumour Biol. 2012 Oct;33(5):1319-26 - PubMed
  25. Mol Cell Proteomics. 2007 Jul;6(7):1115-22 - PubMed
  26. CA Cancer J Clin. 2006 Jan-Feb;56(1):11-25; quiz 49-50 - PubMed
  27. Pak J Med Sci. 2013 May;29(3):885-90 - PubMed
  28. Science. 2003 Apr 25;300(5619):650-3 - PubMed
  29. Head Neck. 2004 Jul;26(7):598-602 - PubMed
  30. Clin Cancer Res. 2008 Nov 1;14(21):6979-87 - PubMed
  31. Cancer. 2013 Jun 15;119(12):2230-8 - PubMed
  32. J Pathol. 1997 Oct;183(2):164-8 - PubMed
  33. Oncol Rep. 2013 Nov;30(5):2297-303 - PubMed
  34. Int J Cancer. 1976 Jan 15;17(1):1-7 - PubMed
  35. Lancet. 2016 Mar 5;387(10022):1012-24 - PubMed
  36. J Proteomics. 2015 Apr 24;119:218-29 - PubMed
  37. J Clin Oncol. 2008 Nov 1;26(31):5060-6 - PubMed
  38. Lancet Oncol. 2012 Aug;13(8):817-26 - PubMed
  39. Clin Cancer Res. 2013 Apr 15;19(8):2175-86 - PubMed
  40. Cancer Prev Res (Phila). 2011 Jul;4(7):1126-34 - PubMed
  41. Cancer Prev Res (Phila). 2014 May;7(5):545-55 - PubMed
  42. Cancer. 2004 Mar 15;100(6):1162-70 - PubMed

Publication Types